Virpax Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jatinder Dhaliwal
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1055 Westlakes Drive Berwyn PA United States of America 19312
- IPO Date
- Feb 17, 2021
- CIK
- 0001708331
- Website
- virpaxpharma.com
- Similar Companies
- Business
- Virpax Pharmaceuticals, Inc. is a specialty biotechnology company developing novel drug delivery platforms designed to advance non-addictive pain management treatments and therapies for central nervous system disorders. The company's pipeline includes several investigational product candidates, such as Epoladerm, a topical spray film formulation of diclofenac epolamine being developed to alleviate chronic pain associated with osteoarthritis of the knee, which is now pursuing an over-the-counter regulatory path. Another key candidate is Probudur, a long-acting injectable liposomal bupivacaine formulation intended for post-operative pain control, which has shown positive preclinical results and is progressing toward an Investigational New Drug application. Additionally, Virpax is advancing Envelta, a nanotechnology-based intranasal spray designed for efficient brain delivery of a peptide for treating various forms of pain, including cancer pain, and post-traumatic stress disorder, with an IND submission anticipated in mid-2024. The company’s portfolio also features AnQlar, an intranasal antiviral barrier developed to help prevent or mitigate viral infections like influenza and SARS-CoV-2, which is being progressed by its new subsidiary, Novvae Pharmaceuticals, focusing on non-prescription products. Furthermore, NobrXiol (previously VRP324) is an investigational intranasal cannabidiol formulation targeted at rare pediatric epilepsy. Founded in 2016, Virpax Pharmaceuticals, Inc. is headquartered in Berwyn, Pennsylvania. The company recently announced a 1-for-25 reverse stock split in March 2025 and received a delisting notice from Nasdaq in April 2025.
Reviewing Virpax Pharmaceuticals (NASDAQ:VRPX) and Zomedica (OTCMKTS:ZOMDF)
Financial Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) versus Merck KGaA (OTCMKTS:MKGAF)
Nabriva Therapeutics (NASDAQ:NBRV) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast
Virpax Pharmaceuticals Announces Reverse Stock Split
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
Virpax's NES100 to be Presented at The Society of Toxicology by NCATS
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher
Why Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?
Spotting Penny Stocks With Breakout Potential, 3 Tips